Selective Targeting of Breast Cancer by Tafuramycin A Using SMA-Nanoassemblies

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of tumors that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein. The mainstay of treatment remains chemotherapy, but the therapeutic outcome remains inadequate. This paper investigates the potential...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2021-06, Vol.26 (12), p.3532
Main Authors: El-Deeb, Ibrahim M., Pittala, Valeria, Eltayeb, Diab, Greish, Khaled
Format: Article
Language:English
Subjects:
Accumulation
Bone marrow
Breast cancer
Cancer therapies
Cell cycle
Chemotherapy
Cytotoxicity
duocarmycin
Encapsulation
EPR effect
ErbB-2 protein
Estrogen receptors
Estrogens
In vivo methods and tests
nanoformulation
Permeability
poly(styrene-co-maleic acid) micelles
Progesterone
Progesterone receptors
Side effects
tafuramycin A
TNBC
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple-negative breast cancer (TNBC) is a heterogeneous subtype of tumors that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein. The mainstay of treatment remains chemotherapy, but the therapeutic outcome remains inadequate. This paper investigates the potential of a duocarmycin derivative, tafuramycin A (TFA), as a new and more effective chemotherapy agent in TNBC treatment. To this extent, we optimized the chemical synthesis of TFA, and we encapsulated TFA in a micellar system to reduce side effects and increase tumor accumulation. In vitro and in vivo studies suggest that both TFA and SMA–TFA possess high anticancer effects in TNBC models. Finally, the encapsulation of TFA offered a preferential avenue to tumor accumulation by increasing its concentration at the tumor tissues by around four times in comparison with the free drug. Overall, the results provide a new potential strategy useful for TNBC treatment.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules26123532